Ziftomenib

Ziftomenib
Clinical data
Trade names	Komzifti
Other names	KO-539; KO539
AHFS/Drugs.com	komzifti
License data	US DailyMed: Ziftomenib;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 4-Methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile;
CAS Number	2134675-36-6;
PubChem CID	138497449;
IUPHAR/BPS	11680;
DrugBank	DB17171;
ChemSpider	115009296;
UNII	4MOD1F4ENC;
KEGG	D12419;
ChEMBL	ChEMBL5095038;
PDB ligand	K5O (PDBe, RCSB PDB);
Chemical and physical data
Formula	C33H42F3N9O2S2
Molar mass	717.88 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F;
	InChI InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1; Key:BGGALFIXXQOTPY-NRFANRHFSA-N;

Ziftomenib, sold under the brand name Komzifti, is an anti-cancer medication used for the treatment of acute myeloid leukemia. Ziftomenib is a menin inhibitor. It is taken by mouth.

Ziftomenib blocks the interaction between two proteins, menin (MEN1) and KMT2A (also known as mixed lineage leukemia protein, MLL).

Ziftomenib was approved for medical use in the United States in November 2025.